Desmoid Tumor of the Head and Neck or Intrathoracic Region: Treatment After Active Surveillance No Longer Controls Growth
Clinical Scenario
This protocol addresses desmoid tumor specifically located in the head and neck, or within the thoracic cavity — anatomical sites that define a distinct clinical population requiring tailored management decisions.
Why This Protocol Is Reached
Initial management with active surveillance (regular clinical and imaging follow-up) did not achieve its intended goals: stable tumor size on imaging and absence of tumor growth across multiple consecutive follow-up appointments. This protocol represents the next management step when surveillance alone is no longer sufficient.
Next-Step Treatment (partial overview)
Medical therapy — involving agents from several distinct therapeutic categories — is initiated for a sustained minimum course duration, with imaging-confirmed tumor stability or reduction at six months as the primary endpoint.
Full regimen options, sequencing, and selection criteria are available in the complete protocol →
References
DOI: 10.1001/jamaoncol.2024.1805
- The consensus of the Desmoid Tumor Working Group was that for most of the available treatments, a course of at least 6 months is required (provided there is absence of frank progression) prior to assessing effectiveness.
- In general and excluding issues of drug availability and cost, which may vary considerably, it is reasonable to use the treatment with more desirable safety profile initially, followed by agents with potentially more toxic effects in a stepwise fashion.
View source ↗